AFT-25 COMET
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Breast, Breast DCIS
Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, & Kootenai Health. Sites must submit to MCC a … Continue reading AFT-25 COMET →
AFT-28 CANVAS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Chronic Lymphocytic Leukemia, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Sarcoma
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) Limited institution study – Only open to: Benefis Sletten Cancer Institute, Billings Clinic, Bozeman Health, Community Hospital of Anaconda, Community Medical Center, Kalispell Regional Medical Center, & Kootenai Health. Sites must submit to MCC an AFT Delegation … Continue reading AFT-28 CANVAS →
AFT-39 PROTECT
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Anal, Bladder, Brain, Breast, Carcinoid, Cervical, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Esophageal, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Liver, Lung, Lung - Non-Small Cell, Lung - Small Cell, Lymphoma, Melanoma, Multiple Myeloma, Neuroendocrine, Ovarian, Pancreatic, Prostate, Rectal, Renal, Sarcoma, Stomach, Thyroid, Uterine
Electronic patient reporting of symptoms during outpatient cancer treatment: A U.S. national randomized controlled trial (the “PRO-TECT” trial) Limited institution study – Only open to: Billings Clinic & Bozeman Health
ALLIANCE A011106
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A Phase III Study Eligible for screening study DCP 001
ALLIANCE A011202
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy Eligible for screening study DCP 001
ALLIANCE A011203
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer A011203 will soon meet its accrual goal. Therefore, EFFECTIVE MONDAY, April 17, 2017 at 4:30 pm ET, A011203 Pre-registration will permanently close to new patient accrual.
ALLIANCE A011401
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Adjuvant Breast, Breast, Breast Neoadjuvant
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer Eligible for screening study DCP 001 The A011401 Health Behaviors and Patient Reported Outcomes substudy HO1 will soon meet its study accrual goal. Therefore, EFFECTIVE July 06, 2017 at 4:30 pm ET, A011401 substudy HO1 … Continue reading ALLIANCE A011401 →
ALLIANCE A011502
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial Eligible for screening study DCP 001
ALLIANCE A021302
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Gastrointestinal, Stomach
Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study Please see additional protocol credentialing requirements for the surgical component (15.1.1), imaging (6.3), and RT (7.3.2). All credentialing requirements must be met prior to patient enrollment. A021302 has been unable to meet required monthly accrual … Continue reading ALLIANCE A021302 →
ALLIANCE A021502
Primary Category:
Treatment Protocols
Disease Category:
Colon, Gastrointestinal
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair Eligible for screening study DCP 001 Site Delegation of Tasks Log required prior to registration of any patients.
ALLIANCE A031102
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors Eligible for screening study DCP 001
ALLIANCE A031201
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Metastatic
Phase III Trial of Enzalutamide (NSC #766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer A031201 will soon meet its accrual goal. Therefore, effective August 31, 2016 at 4:30 PM ET, A031201 will be permanently closed to new patient accrual.
ALLIANCE A031203
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Renal, Renal Metastatic
Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) with Commercially Supplied Sunitinib in Patients with Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma Effective Monday, April 6th, 2015 at 4:30 PM (ET), Alliance A031203 permanently closed to new patient accrual.
ALLIANCE A041202
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia
A Randomized Phase III Study Of Bendamustine PLUS Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone In Untreated Older Patients (≥ 65 Years Of Age) With Chronic Lymphocytic Leukemia (CLL) A041202 will soon meet its accrual goal. Therefore, EFFECTIVE MONDAY, DECEMBER 28, 2015 at 4:30 pm ET, A041202 will permanently close to new patient … Continue reading ALLIANCE A041202 →
ALLIANCE A051301
Primary Category:
Treatment Protocols
Disease Category:
Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype Eligible for screening study DCP 001 Site Delegation of Tasks Log required prior to registration of any patients.
ALLIANCE A061402
Primary Category:
Cancer Control and Prevention Protocols, Treatment Protocols
Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy Eligible for screening study DCP 001
ALLIANCE A071101
Primary Category:
Treatment Protocols
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND #15380) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM) Closed effective 02/21/17
ALLIANCE A071102
Primary Category:
Treatment Protocols
A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation The phase III portion of A071102 will soon meet its accrual goal. Therefore, EFFECTIVE Friday, May 18, 2018 at 4:00 PM ET, A071102 will be PERMANENTLY CLOSED to new patient pre-registration (Step … Continue reading ALLIANCE A071102 →
ALLIANCE A071401
Primary Category:
Treatment Protocols
Status:
Temporarily Closed
Phase II Trial of SMO / AKT / NF2 Inhibitors in Progressive Meningiomas with SMO / AKT / NF2 Mutations The A071401 NF2 Grade I and NF2 Grade II/III cohorts have met their accrual goals. Therefore, EFFECTIVE 07/19/17, no new patients may register (Step 1) to the NF2 Grade I or Grade II/III cohorts. Effective immediately on … Continue reading ALLIANCE A071401 →
ALLIANCE A071601
Primary Category:
Treatment Protocols
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
ALLIANCE A081105
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) (See required screening study ALLIANCE A151216) Eligible for screening study DCP 001
ALLIANCE A091304
Primary Category:
Treatment Protocols
Disease Category:
Sarcoma
A Phase I/ Randomized Phase II Study of MLN0128 Vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma
ALLIANCE A091401
Primary Category:
Treatment Protocols
Disease Category:
Sarcoma
Randomized Phase II Study of Nivolumab with or Without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma As of Update #06, patient enrollment will be facilitated using the Slot Reservation System. Prior to discussing protocol entry with the patient, all site staff must contact MCC to ensure that a slot on the correct cohort is … Continue reading ALLIANCE A091401 →
ALLIANCE A091404
Primary Category:
Treatment Protocols
Disease Category:
Head and Neck
A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers
ALLIANCE A091605
Primary Category:
Radiation Oncology, Treatment Protocols
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
ALLIANCE A151216
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) A screening trial for A081105, E4512, and EA5142. Eligible for screening study DCP 001
ALLIANCE A211401
Primary Category:
Cancer Control and Prevention Protocols, Surgical Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Small Cell
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
ALLIANCE A221102
Primary Category:
Cancer Control and Prevention Protocols
Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias Eligible for screening study DCP 001 A221102 has enrolled sufficient number of patients to meet the study accrual goal. Therefore, EFFECTIVE FRIDAY, December 1, 2017 at 4:30 pm ET, A221102 will permanently close to new patient registration.
ALLIANCE A221208
Primary Category:
Cancer Control and Prevention Protocols, Radiation Oncology
Disease Category:
Brain Metastatic
Randomized Phase II Study: Corticosteroids and Bevacizumab vs. Corticosteroids and Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases Eligible for screening study DCP 001
ALLIANCE A221405
Primary Category:
Cancer Control and Prevention Protocols, Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer Eligible for screening study DCP 001 This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
ALLIANCE A221504
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer (Adenocarcinoma) Eligible for screening study DCP 001
ALLIANCE A221505
Primary Category:
Radiation Oncology, Surgical Protocols
Disease Category:
Adjuvant Breast, Breast
Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction Eligible for screening study DCP 001
ALLIANCE C140503
Primary Category:
Surgical Protocols
Disease Category:
Lung, Lung - Non-Small Cell
A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer (See Section 9.0 for required surgical credentialing.) C140503 has met its accrual goal. Therefore, effective Monday, March 13, 2017 at 4:30 pm EDT, CALGB 140503 will permanently close to new patient pre-registration. Patients that … Continue reading ALLIANCE C140503 →
ALLIANCE C30610
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Limited Stage
Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide Eligible for screening study DCP 001 The QOL Substudy C70702 (embedded in C30610) will soon meet its study accrual goal. Therefore, EFFECTIVE August 30, 2017 at 4:30 pm ET, C70702 will permanently close to new patient accrual.
ALLIANCE C50904
Primary Category:
Treatment Protocols
Disease Category:
Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
A Randomized Phase II Trial of Ofatumumab and Bendamustine VS. Ofatumumab, Bortezomib (NSC #681239, IND #58443) and Bendamustine in Patients with Untreated Follicular Lymphoma (See Section 11.0 for required PET/CT credentialing.) CALGB 50904 has met its accrual goal. Therefore, effective Tuesday, April 5, 2016 at 4:30 PM ET, CALGB 50904 will permanently close to new patient accrual.
ALLIANCE C70807
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Genitourinary, Prostate
The Men’s Eating and Living (MEAL)Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance CALGB 70807 has enrolled sufficient patients to the pre-registration step of the study to meet the registration/randomization accrual goal. Therefore, effective Friday, August 14, 2015 at 5:00 PM ET, CALGB 70807 will be … Continue reading ALLIANCE C70807 →
ALLIANCE C80702
Primary Category:
Treatment Protocols
Disease Category:
Colon, Gastrointestinal
A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer CALGB/SWOG 80702 is nearing its accrual goal. Therefore, effective Friday, November 20th, 2015 at 4:30 PM ET, CALGB/SWOG 80702 will permanently close to new patient accrual.
ALLIANCE C80803
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Esophageal, Gastrointestinal
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer CALGB 80803 has met its accrual goal. Therefore, effective Monday, May 11, 2015 at 4:30 PM (ET), CALGB 80803 will permanently close to new patient accrual.
ALLIANCE C90203
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate
A Randomized Phase III Study of Neoadjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer CALGB 90203 has met its accrual goal. Therefore, effective Friday, October 2nd, 2015 at 4:30 PM EST, CALGB 90203 will permanently close to new patient accrual.
ALLIANCE N0392
Primary Category:
Cancer Control and Prevention Protocols
Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical Trials
ALLIANCE N0577
Primary Category:
Radiation Oncology, Treatment Protocols
Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma Eligible for screening study DCP 001 MCC is a legacy NCCTG institution and site must offer patient participation in N0392 QOL study prior to randomization on N0577. See N0392 … Continue reading ALLIANCE N0577 →
ALLIANCE N1048
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Gastrointestinal, Rectal
A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT) Eligible for screening study DCP 001
DCP 001
Primary Category:
Cancer Control and Prevention Protocols
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
ECOG-ACRIN E1305
Primary Category:
Treatment Protocols
Disease Category:
Head and Neck, Head and Neck Metastatic
A Phase III Randomized Trial of Chemotherapy with or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer
ECOG-ACRIN E1411
Primary Category:
Treatment Protocols
Disease Category:
Lymphoma, Mantle cell Lymphoma, Non-Hodgkin Lymphoma
Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab … Continue reading ECOG-ACRIN E1411 →
ECOG-ACRIN E1412
Primary Category:
Treatment Protocols
Disease Category:
Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma E1412 is successfully approaching its accrual goal, therefore this study will be closed to Step 0 accrual effective January 17, 2017 at 5pm ET.
ECOG-ACRIN E1910
Primary Category:
Treatment Protocols
Disease Category:
Acute Lymphocytic Leukemia, Leukemia
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults Eligible for screening study DCP 001
ECOG-ACRIN E1912
Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia
A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) E1912 will close to Accrual Effective June 9, 2016 at 5:00 pm ET due to reaching its accrual goal.
ECOG-ACRIN E1A11
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE) Eligible for screening study DCP 001 Drug distribution for Carfilzomib is shifting from Fisher Clinical Services to Amgen as of 05/10/17 and Update … Continue reading ECOG-ACRIN E1A11 →
ECOG-ACRIN E2108
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic, Breast Neoadjuvant
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer E2108 is approaching its accrual goal. Therefore, this study closed to accrual effective July 23, 2015 at 5:00 p.m. EDT for Step 1 registrations. Patients already registered to Step 1 may continue … Continue reading ECOG-ACRIN E2108 →
ECOG-ACRIN E2112
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer As described in Section 9.2 of the protocol, accrual of new patients having non- measurable disease only will stop, as the planned accrual of approximately 20% of the target population has been reached. Patients with non-measurable disease only … Continue reading ECOG-ACRIN E2112 →
ECOG-ACRIN E2906
Primary Category:
Treatment Protocols
Disease Category:
Acute Myeloid Leukemia, Leukemia
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥ 60 Years) Eligible for screening study DCP 001
ECOG-ACRIN E3612
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
A Randomized Phase II Trial of Ipilimumab with or without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma E3612 has successfully reached its accrual goal. Therefore, E3612 will close to accrual on September 25, 2017 effective at 5:00 p.m. ET for registrations.
ECOG-ACRIN E3A06
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma E3A06 is successfully approaching its accrual goal. A pending closure date has been set for July 14, 2017 at 5:00pm ET for new patient registration.
ECOG-ACRIN E4512
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (See required screening study ALLIANCE A151216) Eligible for screening study DCP 001
ECOG-ACRIN E5103
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer E5103 Step 3 registration, registration to the EL112LAB substudy, will close to accrual on July 29, 2016.
ECOG-ACRIN E5508
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC E5508 is approaching its Step 1 accrual goal. Therefore, this study will close Step 1 accrual effective May 8, 2015 at 5:00 p.m. EST for registrations. Patients registered … Continue reading ECOG-ACRIN E5508 →
ECOG-ACRIN EA1131
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy Eligible for screening study DCP 001
ECOG-ACRIN EA2142
Primary Category:
Treatment Protocols
Disease Category:
Gastrointestinal, Neuroendocrine
Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas
ECOG-ACRIN EA2161
Primary Category:
Treatment Protocols
Disease Category:
Carcinoid, Gastrointestinal, Neuroendocrine, Pancreatic
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
ECOG-ACRIN EA2165
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Anal, Gastrointestinal
A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
ECOG-ACRIN EA3132
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)
ECOG-ACRIN EA3163
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Head and Neck
Phase II randomized trial of neo-adjuvant chemotherapy followed by surgery and post-operative radiation versus surgery and post-operative radiation for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC)
ECOG-ACRIN EA4151
Primary Category:
Treatment Protocols
Disease Category:
Lymphoma, Mantle cell Lymphoma, Non-Hodgkin Lymphoma
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission Eligible for screening study DCP 001
ECOG-ACRIN EA5142
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Molecular Profiling
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (See required screening study ALLIANCE A151216) Eligible for screening study DCP 001 This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact … Continue reading ECOG-ACRIN EA5142 →
ECOG-ACRIN EA5152
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients with Previously Treated Non-Squamous NSCLC
ECOG-ACRIN EA5161
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
ECOG-ACRIN EA5162
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR
ECOG-ACRIN EA6134
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma Eligible for screening study DCP 001
ECOG-ACRIN EA6141
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
Status:
Temporarily Closed
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma Enrollment is on target to reach the accrual goal necessary to conduct a study-specified planned interim analysis per section 9.4 of the protocol. Only patients who have signed a consent to … Continue reading ECOG-ACRIN EA6141 →
ECOG-ACRIN EA8141
Primary Category:
Surgical Protocols, Treatment Protocols
Disease Category:
Genitourinary, Renal
A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma Arm A of EA8141 will be closed to accrual effective May 31, 2017 at 5PM EST as it will have met its accrual goal. EA8141 is closing due to slow accrual, effective January 5, 2018 at … Continue reading ECOG-ACRIN EA8141 →
ECOG-ACRIN EA8143
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Renal
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) Eligible for screening study DCP 001 Site Delegation of Tasks Log required prior to registration of any patients.
ECOG-ACRIN EA8153
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Metastatic
Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
ECOG-ACRIN EAQ152
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Brain, Breast, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
COMET – Communication and Education in Tumor Profiling: A Randomized Study of Pre-disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling (Sub-study for EAY131) Eligible for screening study DCP 001 MCC not eligible to participate … Continue reading ECOG-ACRIN EAQ152 →
ECOG-ACRIN EAQ162CD
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Cancer Care Delivery, Colon, Gastrointestinal, Rectal
Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent
ECOG-ACRIN EAY131
Primary Category:
Treatment Protocols
Disease Category:
Brain, Breast, Carcinoid, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Lung, Lymphoma, Melanoma, Molecular Profiling, Other, Sarcoma
Molecular Analysis for Therapy Choice (MATCH) Eligible for screening study DCP 001 As of Addendum #10, activated on May 11, 2017, the protocol allows designated private sector laboratories to refer patients to the study based on genetic testing performed independent of MATCH. This is limited to genetic testing ordered for patients at CIRB-approved MATCH trial … Continue reading ECOG-ACRIN EAY131 →
ECOG-ACRIN EAY131-A
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment (See required screening study ECOG-ACRIN EAY131) Open to participants with results from one of the designated outside … Continue reading ECOG-ACRIN EAY131-A →
ECOG-ACRIN EAY131-B
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-B is formally closed to accrual, as it has reached its enrollment goal.
ECOG-ACRIN EAY131-C1
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification (See required screening study ECOG-ACRIN EAY131) Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main … Continue reading ECOG-ACRIN EAY131-C1 →
ECOG-ACRIN EAY131-C2
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion (See required screening study ECOG-ACRIN EAY131) Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of … Continue reading ECOG-ACRIN EAY131-C2 →
ECOG-ACRIN EAY131-E
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR (See required screening study ECOG-ACRIN EAY131) Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) … Continue reading ECOG-ACRIN EAY131-E →
ECOG-ACRIN EAY131-F
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (Other Than Adenocarcinoma of Lung or ALCL) with ALK Translocations (See required screening study ECOG-ACRIN EAY131) Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant … Continue reading ECOG-ACRIN EAY131-F →
ECOG-ACRIN EAY131-G
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol G: Phase II Study of Crizotinib in Patients with ROS1 Translocations (Other Than Patients with Non-Small Cell Lung Cancer) (See required screening study ECOG-ACRIN EAY131) Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific … Continue reading ECOG-ACRIN EAY131-G →
ECOG-ACRIN EAY131-H
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer) (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-H is formally closed to accrual, as it has reached its enrollment goal.
ECOG-ACRIN EAY131-I
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol I: EAY131-I: GDC-0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA mutation but without KRAS mutation or PTEN loss (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-I is formally closed to accrual, as it has reached its enrollment goal.
ECOG-ACRIN EAY131-J
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification (See required screening study ECOG-ACRIN EAY131) The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-237-5467, for the consent & … Continue reading ECOG-ACRIN EAY131-J →
ECOG-ACRIN EAY131-L
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations (See required screening study ECOG-ACRIN EAY131) Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix … Continue reading ECOG-ACRIN EAY131-L →
ECOG-ACRIN EAY131-M
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations (See required screening study ECOG-ACRIN EAY131) Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. … Continue reading ECOG-ACRIN EAY131-M →
ECOG-ACRIN EAY131-N
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol N: EAY131-N: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Mutation or Deletion, with PTEN Expression on IHC (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-N is formally closed to accrual for administrative reasons.
ECOG-ACRIN EAY131-P
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol P: EAY131-P: Phase II Study of PI3K Beta Specific Inhibitor, GSK2636771, in Patients with Tumors with PTEN Loss by IHC (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-P is formally closed to accrual, as it has reached its enrollment goal.
ECOG-ACRIN EAY131-Q
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol Q: Ado-trastuzumab Emtansine in Patients with Tumors with HER2 Amplification (Except Breast and Gastric/Gastro-Esophageal Junction (GEJ) Adenocarcinomas) (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-Q is formally closed to accrual, as it has reached its enrollment goal.
ECOG-ACRIN EAY131-R
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol R: Phase II Study of Trametinib in Patients with BRAF Fusions, or with Non-V600E, Non-V600K BRAF Mutations (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-R is formally closed to accrual, as it has reached its enrollment goal.
ECOG-ACRIN EAY131-S1
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol S1: EAY131-S1: Phase II Study of Trametinib in Patients with Tumors with NF1 mutations (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-S1 is formally closed to accrual, as it has reached its enrollment goal.
ECOG-ACRIN EAY131-S2
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol S2: EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations (See required screening study ECOG-ACRIN EAY131) Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. … Continue reading ECOG-ACRIN EAY131-S2 →
ECOG-ACRIN EAY131-T
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations (See required screening study ECOG-ACRIN EAY131) Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated … Continue reading ECOG-ACRIN EAY131-T →
ECOG-ACRIN EAY131-U
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-U is formally closed to accrual, as it has reached its enrollment goal.
ECOG-ACRIN EAY131-V
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor) (See required screening study ECOG-ACRIN EAY131) Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest … Continue reading ECOG-ACRIN EAY131-V →
ECOG-ACRIN EAY131-W
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-W is formally closed to accrual, as it has reached its enrollment goal.
ECOG-ACRIN EAY131-X
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol X: EAY131-X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-X is formally closed to accrual, as the prevalence rate for the mutation remains at zero.
ECOG-ACRIN EAY131-Y
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-Y is formally closed to accrual, as it has reached its enrollment goal.
ECOG-ACRIN EAY131-Z1A
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-Z1A is formally closed to accrual, as it has reached its enrollment goal.
ECOG-ACRIN EAY131-Z1B
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-Z1B is formally closed to accrual, as it has reached its enrollment goal.
ECOG-ACRIN EAY131-Z1C
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC (See required screening study ECOG-ACRIN EAY131) Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) … Continue reading ECOG-ACRIN EAY131-Z1C →
ECOG-ACRIN EAY131-Z1D
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer) (See required screening study ECOG-ACRIN EAY131) Effective immediately, 06/15/18, EAY131-Z1D is formally closed to accrual, as it has reached its enrollment goal.
ECOG-ACRIN EAY131-Z1E
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions (See required screening study ECOG-ACRIN EAY131) Open to participants with results from one of the designated outside laboratories indicating a “rare variant that is an actionable Mutation of Interest (aMOI) for specific designated rare variant subprotocols. See Appendix XIV of the main protocol … Continue reading ECOG-ACRIN EAY131-Z1E →
ECOG-ACRIN EAY131-Z1I
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
MATCH Treatment Subprotocol Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations (See required screening study ECOG-ACRIN EAY131) The consent form for this sub-study is available upon request when a patient at your site is assigned to the sub-study. Please contact Amber Boerner, aboerner@mtcancer.org or 406-237-5467, for the consent … Continue reading ECOG-ACRIN EAY131-Z1I →
ECOG-ACRIN NHLBI-MDS
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Leukemia, Myelodysplastic Syndrome
The National Myelodysplastic Syndromes (MDS) Study Eligible for screening study DCP 001 This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
ECOG-ACRIN PACCT-1
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial Ancillary study EL112LAB for the PACCT1 Trial has reached its accrual goal. Therefore, PACCT1 Step 3 registration (EL112LAB) will be closed to accrual effective Friday, July 3, 2015 at 5:00 pm EST. (E5103 accrual remains open … Continue reading ECOG-ACRIN PACCT-1 →
GOG Foundation GOG-3015 / Y039523
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian, Ovarian Metastatic
A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Limited institution study: open only to Billings Clinic
NCI 9671
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Molecular Profiling, Other
Exceptional Responders Pilot study: Molecular profiling of tumors from cancer patients who are exceptional responders All cases must be provisionally approved by NCI, before enrollment. Once a case is approved by NCI, then the IRB approval process takes place. Due to the completion of accrual, new case proposal assignments to this protocol will be … Continue reading NCI 9671 →
NRG B-51
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Eligible for screening study DCP 001
NRG B-52
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation B-52 will close to accrual, today, February 29, 2016, effective 8 pm EST. We realize that … Continue reading NRG B-52 →
NRG B-55
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast, Breast Neoadjuvant
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy Eligible for screening study DCP 001
NRG BN003
Primary Category:
Radiation Oncology, Treatment Protocols
Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Eligible for screening study DCP 001
NRG BR002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Breast, Breast Metastatic
A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
NRG BR003
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer Eligible for screening study DCP 001
NRG BR005
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Neoadjuvant
A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery
NRG CC001
Primary Category:
Radiation Oncology, Treatment Protocols
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases Eligible for screening study DCP 001 CC001 will close to accrual at 5 PM ET Monday, March 12, 2018, because it is has reached its accrual target. All patients registered to Step 1 registration by March 12 will be permitted to proceed to … Continue reading NRG CC001 →
NRG CC003
Primary Category:
Radiation Oncology
Disease Category:
Brain, Lung, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage
Status:
Temporarily Closed
Randomized Phase II/III Trial of Prophylatic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer Eligible for screening study DCP 001 NRG CC003 will temporarily close to accrual at 5 pm EST on Friday, October 13, 2017 because it has reached its accrual target for the Phase II component of this study. The study will … Continue reading NRG CC003 →
NRG CC004
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Gynecologic
Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer Eligible for screening study DCP 001 This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or aboerner@mtcancer.org for additional information.
NRG G0225
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Gynecologic
Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival? Eligible for screening study DCP 001
NRG G0237
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
GYN Other
Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (AGC) Eligible for screening study DCP 001
NRG G0263
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Cervical, Gynecologic
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy Eligible for screening study DCP 001
NRG G0270
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Gynecologic
GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) II
NRG G0274
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Cervical, Gynecologic
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial Eligible for screening study DCP 001 Please be aware that as of the 1st June 2017, sites are no longer permitted to screen for or provide informed consent forms for potential OUTBACK/GOG274/RTOG1174 … Continue reading NRG G0274 →
NRG G0281
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer G0281 has met its target accrual goal in the U.S. and the study is no longer accepting any additional specimens for screening. Closure notice to follow soon.
NRG G0286B
Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Endometrial Metastatic, Gynecologic
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer GOG-0286B will be permanently closed to accrual effective today, February 1, 2018 due to futility.
NRG GI002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Gastrointestinal, Rectal
Status:
Temporarily Closed
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer NRG-GI002 accrual will be temporarily suspended on Monday, February, 12 at 4pm EST.
NRG GI004
Primary Category:
Treatment Protocols
Disease Category:
Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer Eligible for screening study DCP 001 Site Delegation of Tasks Log required prior to registration of any patients.
NRG GU001
Primary Category:
Radiation Oncology
Disease Category:
Bladder, Genitourinary
Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer
NRG GU002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
NRG GU003
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) versus Conventional Post-Prostatectomy Radiation Therapy (COPORT) Eligible for screening study DCP 001
NRG GU005
Primary Category:
Radiation Oncology
Disease Category:
Genitourinary, Prostate
Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer Eligible for screening study DCP 001 *RT Credentialing Required **Because the AJCC staging version 8 was not ready for the study activation, AJCC staging version 7 must be used.
NRG GU006
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Recurrent
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer
NRG GY004
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian
A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum sensitive ovarian, fallopian tube, or primary peritoneal cancer Closed to accrual effective November 10, 2017. Accrual goal met. This protocol has additional regulatory requirements to be completed prior to registering any patients … Continue reading NRG GY004 →
NRG GY005
Primary Category:
Treatment Protocols
Disease Category:
Gynecologic, Ovarian
Status:
Temporarily Closed
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS) NRG-GY005: Will temporarily closed to accrual at 5:00 PM ET on June 16, 2017. This protocol has … Continue reading NRG GY005 →
NRG GY006
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Cervical, Gynecologic
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
NRG GY008
Primary Category:
Treatment Protocols
Disease Category:
Endometrial, Gynecologic
Status:
Temporarily Closed
A Phase II Evaluation of Copanlisib (BAY 80-6946) (IND#130822), A Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations Effective immediately, no additional patients will be accepted for PIK3CA mutation screening for NRG-GY008. The stage 1 target accrual is close to being met. This protocol has additional regulatory … Continue reading NRG GY008 →
NRG GY011
Primary Category:
Surgical Protocols
Disease Category:
Endometrial, Gynecologic
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus NRG-GY011 has met its accrual goal and closed to patient entry effective February 9, 2018.
NRG HN002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer Closed effective 02/07/17. Accrual goal met.
NRG HN004
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
Status:
Temporarily Closed
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin HN004 is temporarily closed to accrual effective immediately, 06/13/18, because the first dose level of the lead-in cohort has enrolled 10 patients. The trial will be closed … Continue reading NRG HN004 →
NRG LU001
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC LU001 is closed effective December 15, 2016 because it has reached its accrual target.
NRG LU002
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
NRG R0534
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Recurrent
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy R0534 will close to accrual at 5 PM EST Monday, March 30, 2015, because it is anticipated to have reached its accrual target by that time.
NRG R0724
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Cervical, Gynecologic
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy Eligible for screening study DCP 001
NRG R0815
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer R0815 will close to accrual at 5 PM EST on Monday, March 7, 2016, because the study has reached its accrual target.
NRG R0848
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Gastrointestinal, Pancreatic
A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma Eligible for screening study DCP 001 R0848 will close to accrual at 5 PM ET Friday, June 1, 2018, because it has reached its accrual target. Step 2 randomization … Continue reading NRG R0848 →
NRG R0912
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Thyroid
A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for the Treatment of Anaplastic Thyroid Cancer R0912 is closed to accrual effective December 30, 2016 because it has reached its accrual target.
NRG R0920
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Head and Neck
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer Eligible for screening study DCP 001 R0920 is closed to accrual as of 5 PM ET Tuesday, March 27, 2018, because it has reached its accrual target.
NRG R0924
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Genitourinary, Prostate
Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial (QOL Sub-study is closed as its accrual goal has been met.) Eligible for screening study DCP 001
NRG R1010
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Esophageal, Gastrointestinal
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma R1010 will close to STEP 1 registration at 5 PM EST on Tuesday, November 10, 2015, because the study has reached its accrual target. STEP 2 registration will remain open and all eligible patients determined to be HER2 positive will … Continue reading NRG R1010 →
NRG R1201
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Gastrointestinal, Pancreatic
A Phase II Randomized Trial Evaluating the Addition of High or Standard Intensity Radiation to Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Cancer R1201 is permanently closed to accrual, effective immediately, June 30, 2016. After an accrual assessment by CTEP it was determined that the trial would not be completed within a reasonable timeframe per … Continue reading NRG R1201 →
NRG R1203
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Cervical, Endometrial, Gynecologic
A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C) NRG 1203 closed to accrual at 5 PM EST Thursday, August 27, 2015 because it had reached its accrual target.
NRG R1306
Primary Category:
Radiation Oncology, Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC) R1306 will close to accrual at 5 PM EST Wednesday, December 20, 2017, because we were unable to meet the projected accrual goals due to low prevalence of patients with EGFR mutant and ALK translocation tumors.
SWOG S0931
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Renal
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study S0931 has met its accrual goal and will permanently close to accrual effective September 15, 2016 at 11:59 p.m. Pacific Time.
SWOG S1007
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer S1007 will be permanently closed to accrual for Step 1 … Continue reading SWOG S1007 →
SWOG S1203
Primary Category:
Treatment Protocols
Disease Category:
Acute Myeloid Leukemia, Leukemia
A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) Versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) S1203 is fast-approaching its accrual goal and will permanently close to accrual effective November 4, 2015 at 11:59 pm Pacific Time.
SWOG S1204
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Cancer Care Delivery
A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients (Open only to Billings Clinic) Closed effective 02/15/17. Accrual goal met.
SWOG S1207
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy Eligible for screening study DCP 001
SWOG S1216
Primary Category:
Treatment Protocols
Disease Category:
Genitourinary, Prostate, Prostate Metastatic
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer S1216 has met its accrual goal and will permanently close to accrual effective July 15, 2017 at 11:59 p.m. Pacific.
SWOG S1304
Primary Category:
Treatment Protocols
Disease Category:
Multiple Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease S1304 was temporarily closed to accrual on November 6, 2015. It was anticipated that the study would be re-opened to accrual (subsequent to an accrual target increase due to a higher than anticipated ineligibility rate). … Continue reading SWOG S1304 →
SWOG S1314
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
A Randomized Phase II Study of CO-eXpression ExtrapolatioN (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer S1314 has met its accrual goal and will permanently close to accrual effective December 1, 2017 at 11:59 p.m. Pacific.
SWOG S1320
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
SWOG S1400
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer Eligible for screening study DCP 001
SWOG S1400A
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of MEDI4736 for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-MAP Sub-Study) (See required screening study SWOG S1400) Permanent Closure of S1400A, Arm 2-Docetaxel due to FDA approval of nivolumab. Permanent closure of sub-study due to a revised trial design.
SWOG S1400B
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study) (See required screening study SWOG S1400) S1400B is closed to accrual effective December 12, 2016, as the study did not meet the criterion for the interim futility analysis.
SWOG S1400C
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study) (See required screening study SWOG S1400) Permanent closure of Arm 2 ONLY due to a revised trial design. S1400C will be permanently closed to accrual, effective September 1, 2016, as … Continue reading SWOG S1400C →
SWOG S1400D
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study) (See required screening study SWOG S1400) Effective 11:59 p.m. Pacific Time on October 31, 2016, the following sub-study will be permanently closed to accrual, as the study did not meet the criterion for … Continue reading SWOG S1400D →
SWOG S1400E
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-MET Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study) (See required screening study SWOG S1400)
SWOG S1400F
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of MEDI4736 (Durvalumab) plus Tremelimumab as Therapy for Patients with Previously Treated ANTIPD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-MAP Non-Match Sub-Study) (See required screening study SWOG S1400)
SWOG S1400G
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study) (See required screening study SWOG S1400) Effective June 20, 2018 at 2:00 pm Pacific Time, the following sub-study, S1400G, will be temporarily closed to accrual while data mature to conduct the … Continue reading SWOG S1400G →
SWOG S1400I
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study) Eligible for screening study DCP 001 (See required screening study SWOG S1400) S1400I is permanently closed to accrual effective immediately, 04/23/18. At a planned interim analysis, SWOG’s Data and Safety Monitoring … Continue reading SWOG S1400I →
SWOG S1400K
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Molecular Profiling
A Phase II Study of ABBV-399 (Process II) in Patients with c-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-Study) (See required screening study SWOG S1400)
SWOG S1403
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) S1403 is permanently closed to accrual effective immediately, 04/23/18. Additional information is forthcoming.
SWOG S1404
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Skin
A Phase III Randomized Trial Comparing Physician/Patient Choice of High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma Eligible for screening study DCP 001 Step 1 (prestudy screening) of S1404 study has reached its accrual goal and will be permanently closed to accrual effective August 15, 2017 at 11:59 p.m. Pacific Time. Step … Continue reading SWOG S1404 →
SWOG S1415CD
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Cancer Care Delivery
A Pragmatic Trial Evaluating a Colony Stimulating Factor Intervention in Standing Orders and the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia Limited site participation. Open only to Billings Clinic and Bozeman Health Eligible for screening study DCP 001
SWOG S1416
Primary Category:
Treatment Protocols
Disease Category:
Breast, Breast Metastatic
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer S1416 had an accrual goal of 235 in the main cohort and 98 in the brain metastases cohort for a total of 333 patients. The main cohort is nearing completion of its accrual goal … Continue reading SWOG S1416 →
SWOG S1417CD
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Cancer Care Delivery, Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic
Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer Eligible for screening study DCP 001
SWOG S1418
Primary Category:
Treatment Protocols
Disease Category:
Adjuvant Breast, Breast
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy Eligible for screening study DCP 001 Site Delegation of Tasks Log required prior to registration of any patients.
SWOG S1500
Primary Category:
Treatment Protocols
Disease Category:
Renal, Renal Metastatic
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
SWOG S1501
Primary Category:
Cancer Control and Prevention Protocols
Disease Category:
Breast, Breast Metastatic
Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III Eligible for screening study DCP 001
SWOG S1505
Primary Category:
Treatment Protocols
Disease Category:
Gastrointestinal, Pancreatic
A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma S1505 will be permanently closed to accrual effective April 20, 2018 at 11:59 p.m. Pacific Time.
SWOG S1507
Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
A Phase II Trial of Trametinib with Docetaxel in Patients with Kras Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies S1507 has met its accrual goal and will permanently close to accrual effective March 15, 2018 at 11:59 p.m. Pacific.
SWOG S1512
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Skin
A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)
SWOG S1513
Primary Category:
Treatment Protocols
Disease Category:
Gastrointestinal, Pancreatic, Pancreatic Metastatic
Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer S1513 is permanently closed to accrual effective immediately. 12/13/17. At a planned interim analysis, our Data and Safety Monitoring Committee recommended that S1513 be closed permanently based on the results. These results will … Continue reading SWOG S1513 →
SWOG S1602
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer Eligible for screening study DCP 001
SWOG S1605
Primary Category:
Treatment Protocols
Disease Category:
Bladder, Genitourinary
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
SWOG S1607
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
A Phase II Study of Combining T-VEC (NSC-785349) and Pembrolizumab (NSC-776864) in Patients with Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy Limited institution study: open only to Billings Clinic
SWOG S1608
Primary Category:
Treatment Protocols
Disease Category:
Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
SWOG S1609
Primary Category:
Treatment Protocols
Disease Category:
Molecular Profiling
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Eligible for screening study DCP 001 Please see http://www.swogstat.org/accrual/dart.htm for up-to-date accrual information and current cohort accrual status (i.e. open, closed, suspended). The website is updated with the most current information daily.
SWOG S1612
Primary Category:
Treatment Protocols
Disease Category:
Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndrome
A Randomized Phase II/III Trial of “Novel Therapeutics” versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older
SWOG S1613
Primary Category:
Treatment Protocols
Disease Category:
Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic
A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification
SWOG S1616
Primary Category:
Treatment Protocols
Disease Category:
Melanoma, Metastatic Melanoma, Skin
A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) OR Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD-1 or Anti PD-L1 Agent
SWOG S1619
Primary Category:
Radiation Oncology, Surgical Protocols, Treatment Protocols
Disease Category:
Lung, Mesothelioma
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma Eligible for screening study DCP 001
SWOG S1702
Primary Category:
Treatment Protocols
A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
